Results 21 to 30 of about 180,701 (284)

Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil

Vaccines, 2021
The present study evaluated the frequency of seropositivity for anti-SARS-CoV-2 (S1 and S2) total antibodies and anti-SARS-CoV-2 (receptor binding domain-RBD-S1) neutralizing antibodies in individuals vaccinated with the immunizing agent Coronavac.
Carlos David Araújo Bichara, Maria Alice Freitas Queiroz, Ednelza da Silva Graça Amoras, Gergiane Lopes Vaz, Izaura Maria Vieira Cayres Vallinoto, Cléa Nazaré Carneiro Bichara, Isabella Pinheiro Costa do Amaral, Ricardo Ishak, Antonio Carlos Rosário Vallinoto   +8 more
doaj   +1 more source

SARS-CoV-2 neutralizing antibody development strategies

TURKISH JOURNAL OF BIOLOGY, 2020
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020 ...
Bertan Koray BALCIOĞLU, Melis DENİZCİ ÖNCÜ, Hasan Ümit ÖZTÜRK, Fatıma YÜCEL, Filiz KAYA, Müge SERHATLI, Hivda ÜLBEĞİ POLAT, Şaban TEKİN, Aylin ÖZDEMİR BAHADIR   +8 more
openaire   +3 more sources

Distinct Antibody Responses to Endemic Coronaviruses Pre- and Post-SARS-CoV-2 Infection in Kenyan Infants and Mothers

Viruses, 2022
Pre-existing antibodies that bind endemic human coronaviruses (eHCoVs) can cross-react with SARS-CoV-2, which is the betacoronavirus that causes COVID-19, but whether these responses influence SARS-CoV-2 infection is still under investigation and is ...
Caitlin I. Stoddard, Kevin Sung, Ednah Ojee, Judith Adhiambo, Emily R. Begnel, Jennifer Slyker, Soren Gantt, Frederick A. Matsen, John Kinuthia, Dalton Wamalwa, Julie Overbaugh, Dara A. Lehman   +11 more
doaj   +1 more source

Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 [PDF]

, 2020
Background and purpose Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported.
Boon, Paul, De Herdt, Veerle, Garrez, Ieme, Hemelsoet, Dimitri, Laureys, Guy, Raedt, Robrecht, Vonck, Kristl   +6 more
core   +2 more sources

Neurological Complications in COVID-19 Patients: Can Analysis of Specific Antibodies and Viral RNA in Paired Cerebrospinal Fluid and Serum be Used for Accurate Diagnosis of SARS-CoV-2 Neuroinflammatory Disease? A Case Series

Clinical Pathology, 2022
Background: Neurological complications during and after SARS-CoV-2 infection have been frequently described. The detection of either SARS-CoV-2 RNA or specific antibodies against SARS-CoV-2 in cerebrospinal fluid in the context of concomitant ...
Karin Holst Lauridsen, Kristine Boisen Olsen, Eva Løbner Lund, Tomas O Jensen, Thomas Ingemann Pedersen, Zitta Barrella Harboe, Valeria Antsupova, Lasse Dam Rasmussen, Dennis Röser, Jytte Banner, Kristina Træholt Franck, Veronika Vorobieva Solholm Jensen   +11 more
doaj   +1 more source

Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection

Frontiers in Immunology, 2022
A novel coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged and caused an outbreak of unusual viral pneumonia.
Kyu-Young Sim, Kyu-Young Sim, Gwang-Hoon Ko, So-Eun Bae, Kyu Yeong Choi, Jung Sup Lee, Jung Sup Lee, Jung Sup Lee, Byeong C. Kim, Byeong C. Kim, Kun Ho Lee, Kun Ho Lee, Kun Ho Lee, Mi-Ryoung Song, Sung-Gyoo Park   +14 more
doaj   +1 more source

Evolution of antibody immunity to SARS-CoV-2 [PDF]

Nature, 2020
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 million deaths to date. Infection is associated with development of variable levels of antibodies with neutralizing activity that can protect against infection in animal models.
Gaebler, Christian, Wang, Zijun, Lorenzi, Julio C. C., Muecksch, Frauke, Finkin, Shlomo, Tokuyama, Minami, Cho, Alice, Jankovic, Mila, Schaefer-Babajew, Dennis, Oliveira, Thiago Y., Cipolla, Melissa, Viant, Charlotte, Barnes, Christopher O., Bram, Yaron, Breton, Gaëlle, Hägglöf, Thomas, Mendoza, Pilar, Hurley, Arlene, Turroja, Martina, Gordon, Kristie, Millard, Katrina G., Ramos, Victor, Schmidt, Fabian, Weisblum, Yiska, Jha, Divya, Tankelevich, Michael, Martinez-Delgado, Gustavo, Yee, Jim, Patel, Roshni, Dizon, Juan, Unson-O’Brien, Cecille, Shimeliovich, Irina, Robbiani, Davide F., Zhao, Zhen, Gazumyan, Anna, Schwartz, Robert E., Hatziioannou, Theodora, Bjorkman, Pamela J., Mehandru, Saurabh, Bieniasz, Paul D., Caskey, Marina, Nussenzweig, Michel C.   +41 more
openaire   +4 more sources

Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia

International Journal of Infectious Diseases, 2021
: Background: As healthcare workers (HCWs) are at high risk for infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), they have priority for receipt of the coronavirus disease 2019 (COVID-19) vaccine.
Cucunawangsih Cucunawangsih, Ratna Sari Wijaya, Nata Pratama Hardjo Lugito, Ivet Suriapranata   +3 more
doaj   +1 more source

Monoclonal antibody therapies against SARS-CoV-2

The Lancet Infectious Diseases, 2022
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and ...
Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M   +5 more
openaire   +2 more sources

The Antibody Response to SARS-CoV-2 Infection [PDF]

Open Forum Infectious Diseases, 2020
AbstractBackgroundTesting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies has become an important tool, complementing nucleic acid tests (NATs) for diagnosis and for determining the prevalence of coronavirus disease 2019 (COVID-19) in population serosurveys.
Linda Hueston, Jen Kok, Ayla Guibone, Damien McDonald, George Hone, James Goodwin, Ian Carter, Kerri Basile, Indy Sandaradura, Susan Maddocks, Vitali Sintchenko, Nicole Gilroy, Sharon Chen, Dominic E Dwyer, Matthew V N O’Sullivan   +14 more
openaire   +4 more sources